An Escalating, Multiple-Dose Study in Ragweed Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Ragweed.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs Ragweed SPIRE (Primary)
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Circassia
- 12 Feb 2010 Interim results reported in a Circassia media release.
- 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History